3 Small-Cap Dividend-Paying Healthcare Stocks Compared With Pfizer

Published Sat, 31 May 2014 21:30 CET by DividendYields.org

Investing in dividend paying stocks is an ideal approach to turbo charge the stock portfolio and also to buffer oneself against the vagaries of stock movement. Choosing a stock from a mature sector is a good idea, as the valuations would not be too high and there would be future stable growth. One such sector is healthcare. The healthcare sector consumed an average of 9.3% of the GDP across the OECD countries as a whole. Within the US this is even higher at 17.7% and it is in double digits in most of the countries, including The Netherlands (11.9%), France (11%), Germany (11.3%) and so on. There is ample scope of future growth in this sector, because of an ageing population requiring higher expenditure on healthcare vis-à-vis other sectors. Below are some stocks that might be interesting choices for investors looking for attractive dividends.

Meridian Bioscience (Nasdaq: VIVO) produces a range of diagnostic test kits. The top line for this company has been growing at a steady pace and the net margins are in the double digits. One another good aspect of this company is that it has zero debt on its balance sheet. It yielded 3.9% recently and its dividend has been increasing at a steady pace of 4% for the past 5 years. The payout ratio is 65% and is thus in a comfort zone. It recently received FDA approval for a new test on Bordetella Pertussis, which is the causing agent of whopping cough. This test can lead to improved sales later this year. The company is operating in three segments: Life Science, U.S Diagnostics and European Diagnostics. Although the dividend growth for the past 5 years has been a lowly 3.20%, higher growth is predicted in the future as management has started taking concentrated steps to improve overall efficiency.

PetMed Express (Nasdaq: PETS) is an online pet pharmacy, offering prescription and non-prescription medications, as well as other health products, for pets. It gives a dividend yield of 5.08% and has a comfortable P/E ratio of 14.87. Net sales were up 2.5% and net margin was up 4.7% from the year earlier. There has been a decrease in operating expenses by 83 basis points and the company is trying to bring greater efficiency across their distribution channel. The payout ratio is 76%, which is a bit on the higher side and might cause the company to reduce the dividend in the future, unless it is able to get excellent growth. Another major point to note is that the company is facing increasing competitive pressure which will only increase in the future after the acquisition of Novartis’ animal health division by pharmaceutical major Eli Lilly. While bears worry about the competitive pressure and lower growth, the bears like the new steps taken by the management and the current valuation of the company. As the company is dealing with mostly sales of pet products directly to customers, the overall operating margin is bound to be on the lower side compared to other healthcare firms involved in research and diagnostics. For the past 5 years the dividend growth has been a healthy 11.2% on the back of improved profitability. This, added to the fact that the P/E ratio is on the lower side, gives the investor the double benefit of future growth in the value of the stock and higher dividends.

Psychemedics (Nasdaq: PMD) is the world's leading drug testing company using hair for the detection of drugs of abuse. Its dividend yield is 4.20% and its payout ratio is 82%. The P/E ratio for the stock is 19.5, which shows that it is not overvalued. As the overall business model is unique, there is less competition and the company has shown stable growth for the past several years. The dividend has also increased for the past 5 years and the outlook for the company is stable. It provides testing and confirmation of drug abuse using mass spectrometry. Drugs covered are marijuana, methamphetamine, phencyclidine (PCP), cocaine and other opiates. The dividend growth has been on the lower side for the past 5 years and hovering around less than 5% per annum. The operating margin has been stable at 21.24% and given the future scope of the business, there does not seem to be heavy improvement in this area. However, the stock offers a good diversification option as it is involved in a niche area within healthcare industry where the demand would continue to show growth for the next couple of years.

Meridian Bioscience PetMed Express Psychemedics Pfizer
Market Cap $884 mil $269 mil $75.1 mil $189 bil
Payout Ratio 65% 76% 82% 64%
Price/Earnings 23.6 14.9 20.0 18.0
Earnings Per Share 0.88 0.90 0.72 1.64
Dividend Growth Per Annum (5 Yrs) 3.30% 11.2% 4.56% 10.2%
Operating Margin (2013) 30.38% 11.85% 21.24% 31.32%


One can also go for a blue chip healthcare stock like Pfizer (NYSE: PFE). It has a yield of 3.53% and a payout ratio of 64%. Its P/E ratio is 18 and the company is known for a stable and diverse business portfolio, which can give a decent yield in the future and can also protect against major swings in the market. Although the dividend yield is not as high as some small healthcare stocks, being a major healthcare blue chip company investors can be assured of decent capital appreciation over a long term if they invest the dividend back into the stock. Pfizer has a healthy operating margin of above 30% and has shown a dividend growth of 10.19% for the past 5 years. Being a well-diversified group, this is very interesting for investors interested in investing in the healthcare sector.

Small Cap Healthcare Stocks Compared With Pfizer Performance Graph

According to the graph above, Pfizer and Psychemedics have performed better than the Dow Jones Industrial Average over the past 5 years, whereas the other two companies have not shown requisite capital appreciation in their stocks. However, purchasing the latter two currently can help in riding on any future upswing in the valuation of these companies. This, coupled with the high dividend return of the companies, can be a double incentive to purchase these stocks.
Stock name Dividend Yield
Pfizer 3.67
Meridian Bioscience 3.53
Psychemedics 2.86
Petmed Express 2.12

Articles featuring Pfizer (PFE):

My Dividend Growth Portfolio - Q2 2018 Summary

Introduction It's time to summarize another quarter. This quarter came after a mediocre quarter for me. The first month was a direct continuation of the first quarter. My portfolio suffered from negative returns while the other two months made up for it. The total return in Q2 was 2.2%, which is lower than the S&P 500 which I use as my benchmark. While it's not my ultimate benchmark, I still compare my performance to the S&P 500 as it shows an alternative way of investing.... Read more

Jane's June Dividend Increases And Income - Retirement Accounts

Investment Thesis June marks the fourth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the taxable account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a number of stocks in her retirement accounts that didn't register their first dividend until April or May. Now that the majority of companies are seasoned, we are seeing a steady stream of dividend... Read more

Dividend News: Strong Economy Fueling Distribution Hikes, Special Dividends

Stocks Drop on Trade Fears U.S. stocks plunged at the start of Wednesday’s session, as trade tensions between the U.S. and other major countries intensified. The Dow opened the trading day lower by about 210 points. The tech-heavy Nasdaq and broader-based S&P 500 indices also opened the session with steep losses. Traders bid up the price of U.S. government debt to avoid the turmoil. The yield on the 10-year Treasury note dropped to around 2.84%, while the yield on the... Read more

Top 'Safer' Dividend Big Gain Dow Stocks: Caterpillar, DowDuPont; McDonald's, United Technologies, And Boeing, Per Broker July Metrics

Actionable Conclusions (1-10): Analysts Estimated Net Gains of 14.72% By July Dividend Dow Index Stocks Six of the ten top "safer" dividend Dow dogs by yield (shaded in the chart above) were among the top ten gainers for the coming year based on analyst 1-year target prices. Thus, June estimates showed as 60% accurate. Projections based on estimated dividend returns from $1000 invested in each of the thirty highest-yielding stocks and their aggregate 1-year analyst median target... Read more

Dividend Portfolio Review: Top 2 Dividend Income For June

As the stakes are increasing with the U.S - China - EU trade wars German automobile stocks get pummeled and are trading at valuations not having been seen since the British cast their infamous BreXit vote. With markets becoming increasingly subject to Trump's intensified everyday Twitter activities windows of opportunity are opening and closing at rapid pace. In that environment it is important to stay true to your strategy and remain committed to your goals. However, this does not... Read more